Tipifarnib

Vladimir Beljanski

doi:10.1016/B978-008055232-3.64493-9

Tipifarnib

Vladimir Beljanski

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Tipifarnib, an orally administered non-peptidomimetic farnesyl transferase inhibitor, has shown promising clinical activity. Farnesyl transferase inhibitors are a novel class of anticancer agents that competitively inhibit farnesyltransferase, an enzyme that is essential for farnesylation. Farnesylation leads to oncogene Ras activation, and to the development of neoplasms. The mechanism of action of this class of anticancer drugs appears complex, involving proteins in addition to Ras. Preliminary results from clinical trials demonstrate enzyme target inhibition, low toxicity and promising clinical activity. .... . © 2009

Original language	English
Title of host publication	xPharm
Subtitle of host publication	The Comprehensive Pharmacology Reference
Editors	S.J. Enna, David B. Bylund
Publisher	Elsevier Inc.
Pages	1-4
Number of pages	4
ISBN (Print)	9780080552323
DOIs	https://doi.org/10.1016/B978-008055232-3.64493-9
State	Published - 2009
Externally published	Yes

ASJC Scopus Subject Areas

General Pharmacology, Toxicology and Pharmaceutics

Disciplines

Medicine and Health Sciences

Access to Document

10.1016/B978-008055232-3.64493-9

Cite this

@inbook{49324d7073744fc1b65a68efba63a283,

title = "Tipifarnib",

abstract = "Tipifarnib, an orally administered non-peptidomimetic farnesyl transferase inhibitor, has shown promising clinical activity. Farnesyl transferase inhibitors are a novel class of anticancer agents that competitively inhibit farnesyltransferase, an enzyme that is essential for farnesylation. Farnesylation leads to oncogene Ras activation, and to the development of neoplasms. The mechanism of action of this class of anticancer drugs appears complex, involving proteins in addition to Ras. Preliminary results from clinical trials demonstrate enzyme target inhibition, low toxicity and promising clinical activity. .... . {\textcopyright} 2009",

author = "Vladimir Beljanski",

year = "2009",

doi = "10.1016/B978-008055232-3.64493-9",

language = "English",

isbn = "9780080552323",

pages = "1--4",

editor = "S.J. Enna and Bylund, \{David B.\}",

booktitle = "xPharm",

publisher = "Elsevier Inc.",

address = "United States",

}

TY - CHAP

T1 - Tipifarnib

AU - Beljanski, Vladimir

PY - 2009

Y1 - 2009

N2 - Tipifarnib, an orally administered non-peptidomimetic farnesyl transferase inhibitor, has shown promising clinical activity. Farnesyl transferase inhibitors are a novel class of anticancer agents that competitively inhibit farnesyltransferase, an enzyme that is essential for farnesylation. Farnesylation leads to oncogene Ras activation, and to the development of neoplasms. The mechanism of action of this class of anticancer drugs appears complex, involving proteins in addition to Ras. Preliminary results from clinical trials demonstrate enzyme target inhibition, low toxicity and promising clinical activity. .... . © 2009

AB - Tipifarnib, an orally administered non-peptidomimetic farnesyl transferase inhibitor, has shown promising clinical activity. Farnesyl transferase inhibitors are a novel class of anticancer agents that competitively inhibit farnesyltransferase, an enzyme that is essential for farnesylation. Farnesylation leads to oncogene Ras activation, and to the development of neoplasms. The mechanism of action of this class of anticancer drugs appears complex, involving proteins in addition to Ras. Preliminary results from clinical trials demonstrate enzyme target inhibition, low toxicity and promising clinical activity. .... . © 2009

UR - https://www.scopus.com/pages/publications/84884102989

UR - https://www.scopus.com/pages/publications/84884102989#tab=citedBy

U2 - 10.1016/B978-008055232-3.64493-9

DO - 10.1016/B978-008055232-3.64493-9

M3 - Chapter

AN - SCOPUS:84884102989

SN - 9780080552323

SP - 1

EP - 4

BT - xPharm

A2 - Enna, S.J.

A2 - Bylund, David B.

PB - Elsevier Inc.

ER -

Tipifarnib

Abstract

ASJC Scopus Subject Areas

Disciplines

Access to Document

Other files and links

Fingerprint

Cite this